1
EXHIBIT 11
STATEMENT REGARDING COMPUTATION OF EARNINGS PER SHARE
DURAMED PHARMACEUTICALS, INC. AND SUBSIDIARIES
Three months ended Six Months Ended
June 30, June 30,
1996 1995 1996 1995
-------------------------------------------------------
Primary:
Weighted average common shares
outstanding 10,122,713 8,012,287 9,344,296 7,998,260
Assumed conversion of preferred
shares to common shares * 746,590 * 746,590
Net effect of dilutive stock options
and warrants - based on the
treasury stock method using the
average market price * 1,940,198 * 1,960,288
----------- ----------- ----------- -----------
Totals 10,122,713 10,699,075 9,344,296 10,705,138
=========== =========== =========== ===========
Net (loss) income ($ 1,875,736) $ 632,483 ($4,311,749) $ 1,640,830
=========== =========== =========== ===========
Per share amount $ (.19) $ .06 $ (.46) $ .15
=========== =========== =========== ===========
Fully diluted:
Weighted average common shares
outstanding 10,122,713 8,012,287 9,344,296 7,998,260
Assumed conversion of preferred
shares to common shares * 746,590 * 746,590
Net effect of dilutive stock options
based on the treasury stock method
using the year-end market price, if
higher than average market price * 1,940,198 * 1,961,575
----------- ----------- ----------- -----------
Totals 10,122,713 10,699,075 9,344,296 10,706,425
=========== =========== =========== ===========
Net (loss) income ($ 1,875,736) $ 632,483 ($4,311,749) $ 1,640,830
=========== =========== =========== ===========
Per share amount $ (.19) $ .06 $ (.46) $ .15
=========== =========== =========== ===========
*Conversion of stock options and preferred shares not assumed in the
computations because their effect is antidilutive.
-20-